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Interleukin-1 is a proinflammatory cytokine implicated
under pathological conditions involving NMDA receptor acti-
vation, including the AIDS dementia complex (HAD). No infor-
mation is available on the molecular mechanisms recruited by
native interleukin-1 produced under this type of condition.
Using a sandwich co-culture of primary hippocampal neurons
and glia, we investigatedwhether native interleukin-1 released
by HIV-gp120-activated glia (i) affects NMDAR functions and
(ii) the relevance on neuronal spine density and survival, two
specific traits of HAD. Increased phosphorylation of NR2BTyr-
1472 was observed after 24 h of exposure of neurons to 600 pM
gp120. This effect occurred only when neurons were treated in
the presence of glial cells andwas abolished by the interleukin-1
receptor antagonist (IL-1ra). Gp120-induced phosphorylation
ofNR2Bresulted in a sustained elevationof intracellularCa2 in
neurons and in a significant increase ofNR2Bbinding toPSD95.
Increased intracellular Ca2was prevented by 10M ifenprodil,
that selectively inhibits receptors containing the NR2B, by
interleukin-1ra and by Ca-pYEEIE, a Src family SH2 inhibitor
peptide. These last two inhibitors, prevented alsoNR2B binding
to PSD95. Finally, gp120 reduced by 35% of the total PSD95
positive spine density after 48 h of treatment and induced by
30% of the neuronal death. Again, both of these effects were
blocked by Ca-pYEEIE. Altogether, our data show that gp120
releasing interleukin-1 from glia increases tyrosine phospho-
rylation of NMDAR. Thus, tyrosine phosphorylation may con-
tribute to the sensitization of the receptor increasing its func-
tion and synaptic localization. Both of these effects are relevant
for neurodegeneration.
Interleukin-1 (IL-1)3 has been proposed as a novel neuro-
modulator involved in the communication between glia and
neurons (1–4), opening up new perspective in the current view
of brain behavior. This cytokine, locally produced by glial cells
as a consequence of CNS diseases and/or in response to neuro-
nal activities (4), exerts a profound impact on neuronal func-
tionality through a specific receptor. So far, IL-1 has been
implicated in the exacerbation of neuronal damage caused by
excitotoxic, ischemic, traumatic brain injury (5, 6), and viral
infection (AIDS dementia complex: HAD) (7–9), in seizures
(10) as well as in physiological events such as long-term poten-
tiation (11, 12), sleep (13), memory consolidation (14, 15), and
pain (16). Although IL-1 may offer exciting potential in the
discovery of novel targets to modulate brain behavior, the bio-
chemical pathways specifically recruited in neurons by this
cytokine have not been explored in detail.
Recombinant IL-1 potentiates calcium response and neu-
ronal death achieved through NMDA receptor activation in
primary hippocampal neurons by increasing phosphorylation
of NR2B tyrosine 1472 (17). Tyrosine phosphorylation of NR2
subunits has been involved in NMDAR channel gating, protec-
tion of NR2 subunits against degradation by calpain, assembly
with signaling proteins andNMDAR trafficking (18–20), and it
is therefore relevant in the dynamic modulation of NMDARs.
The ability of IL-1 to specifically recruit NR2 tyrosine phos-
phorylation in neurons (17, 18) could provide a plausible bio-
chemical explanation of the effects exerted in vivo by this cyto-
kine and supports IL-1 as a neuromodulator possibly involved
in those physiological and pathological aspects relying on
NMDAR.
IL-1 enhancement of NMDA functions may represent an
important part of the complex cascade of events in AIDS
dementia complex (HAD). It is well established that overstimu-
lation of NMDAR represents a key event in HAD (21, 22), the
most common cause of dementia worldwide among people
aged 40 or less (23). Behavioral symptoms characteristic of
HAD such as cognitive decline, personality change, and motor
deficits (24, 25) appear to be consequent to decreased synaptic
density, spine loss, dendritic simplification, and neuronal loss
(26, 27) all of which are thought to result from release of toxic
factors from activated macrophages and glial cells (21, 28). At
themoment, no information is available on the possible recruit-
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ment of NR2 subunits, Tyr phosphorylation in HAD, and the
involvement of glial released IL-1.
To test this hypothesis we exposed primary hippocampal
neurons and glial cells to HIV-envelope glycoprotein gp120,
considered one of the pathological agents of HAD (29). We
then examined NR2B Tyr-1472 phosphorylation in neurons,
part of the pathway leading to this process and the relevance on
intracellular Ca2 homeostasis. Finally, we evaluated the func-
tional consequences of two hallmarks of HAD: dendritic spine
density and neuronal survival.
EXPERIMENTAL PROCEDURES
Sandwich Co-cultures of Hippocampal Neurons and Glial
Cells—Primary cultures of glial cells were prepared from 1- to
2-day-old newborn rats (Sprague-Dawley). All animal care pro-
cedures were in accordance with the local Animal Care Com-
mittee, and noweight loss or deathwas observed after receipt of
rats in our animal facility. Pregnant rats were housed overwood
chip bedding, acclimatized to a 12-h light-dark cycle and
allowed food and water ad libitum. All efforts were made to
minimize the suffering of animals.
Cerebral hemispheres were freed from the meninges and
mechanically disrupted. Cells were dispersed in a solution of
trypsin 2.5% and DNase 1%, filtered through a 100-mm nylon
mesh and plated (140,000 cells per 35-mm dish) in Eagle’s min-
imum essential medium (MEM) supplemented with 10% fetal
calf serum, 0.6% glucose, streptomycin (0.1 mg/ml), and peni-
cillin (100 international units/ml). Glial cultures were fed twice
a week and grown at 37 °C in a humidified incubator with 5%
CO2.
Neuronal cultureswere established from thehippocampus of
18-day rat fetuses. Briefly, brains were removed and freed from
meninges, and the hippocampus was isolated. Cells were then
dispersed by incubation for 5 min at 37 °C in a 2.5% trypsin
solution followed by trituration. The cell suspension was
diluted in Neurobasal media supplemented with 1% B-27
(Invitrogen) and plated onto polyornithine-coated coverslips at
a density of 80,000 cells per coverslip. Three days before treat-
mentwith gp120, coverslips were transferred to dishes contain-
ing a glial monolayer in neuron maintenance medium. Cover-
slips were inverted so that the hippocampal neurons faced the
glia monolayer; both cell preparations were immersed in the
same culture medium. Paraffin dots adhering to the coverslips
supported them above the glia, creating a narrow gap that pre-
vented the two cell types from contacting each other but
allowed the diffusion of soluble substances. These culture con-
ditions allowed us to growdifferentiated neuronal cultureswith
96% homogeneity, as assessed by immunocytochemistry of
microtubule-associated protein 2 and glial fibrillary acidic pro-
tein (Molecular Probes). Hippocampal neurons were used after
a culturing period of 14 days.
Gp120 and Treatments—Recombinant HIV-gp120 protein
type IIIB (Bartels, Carlsbad, CA) was used in all the experi-
ments. Neurons were exposed to drugs in their culturemedium
(Neurobasal media supplemented with 1% B-27). Treatment
with the glycoprotein was mainly performed in the presence of
glia. To this purpose, primary hippocampal neurons were
transferred on a glial monolayer for 3 days before exposure to
gp120. Glass coverslips with primary hippocampal neurons
were detached from the glial monolayer at the end of the expo-
sure and assessed for NMDAR Tyr phosphorylation and traf-
ficking, Ca2 homeostasis, cell fractionation, confocal micros-
copy, and cell death.
1 g/ml human recombinant IL-1ra (R&D Systems, Minne-
apolis, MN), 10 M ifenprodil hemitartrate (Tocris, Bristol,
UK), 10 M TAT-2B (Primm, Milano, Italy) were incubated
with gp120 and kept in the incubation medium until the end of
the treatment. In contrast, 10 g/ml caffeic acid-pYEEIE (Ca-
pYEEIE; Tocris) was delivered only in primary hippocampal
neurons, prior to gp120 treatment, by means of the lipid base
transfection reagentChariot (ActiveMotif, Rixensart, Belgium)
according to supplier instructions. Briefly, caffeic acid-pYEEIE
was incubated with Chariot dilution at room temperature for
30 min to allow the formation of the Chariot-molecule com-
plex. Neuronal cells without glia were then overlaid with the
Chariot-macromolecule complex solution diluted in Neuro-
basal and incubated at 37 °C for 1 h. At the end, complete
growth medium was added, and incubation continued for
another hour. Ca-pYEEIE loaded neurons were then washed to
remove extracellular Ca-pYEEIE and transferred to the glial
monolayer for gp120 exposure. Control neuronal cultures were
run in parallel under each experimental condition and incu-
bated for the appropriate times in the presence or absence of
glia.
IL-1 Assay—IL-1 release was measured by means of an
interleukin-1L rat ELISA system (Quantikine, R&D Systems,
Abingdon, UK).
Determination of the Cytosolic-free Ca2 Concentration
[Ca2]i—At the end of exposure to gp120, neurons on glass
coverslips were detached from glial cells and loaded with 10M
Fura 2-AM (Sigma) for 1 h at 37 °C in the treatment culture
medium supplemented with 1% bovine serum albumin, 0.1%
pluronic (Sigma). [Ca2]imeasurement was performed in neu-
rons only in Hepes buffer, pH 7.4, as previously described (9).
The Fura 2 fluorescence ratio signal was measured in a
PerkinElmer Life Sciences 50 B double wavelength fluorometer
and calibrated in terms of [Ca2]i as described by Grynkiewicz
et al. (30).
Immunofluorescence Labeling, Image Acquisition, and
Quantification—Hippocampal neurons were fixed in 100%
methanol at20 °C for 15 min. Primary and secondary anti-
bodies were applied in GDB buffer (30 mM phosphate buffer
(pH 7.4) containing 0.2% gelatin, 0.5% Triton X-100, and 0.8
M NaCl). Fluorescence images were acquired using Bio-Rad
Radiance 2100 confocal microscope. Confocal images were
obtained using a Nikon 60 objective with sequential acqui-
sition setting at 1024  1024 pixel resolution. Each image
consisted of a z-stack of pictures taken at a depth interval of
0.1mand then projected into one image. Both image acqui-
sition and quantification of the fluorescence signal were per-
formed by operators blind to the experimental condition.
PSD-95 staining puncta were defined by thresholding images
at three times the backgroundmeasured within the dendritic
shaft. The ratio of average immunofluorescence intensity
between the spine head and the dendritic shaft next to it was
measured on manually selected spine head and dendritic
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shaft areas. Neurons selected for analysis had a similar local
environment; synapses on soma were not analyzed. For sta-
tistical analysis of spine number, a dendritic shaft of 100 m
starting from the cell soma from 12 neurons for each exper-
imental condition was analyzed. Colocalization analysis was
performed using Bio-Rad Laserpix software.
Subcellular Fractionation—Triton-insoluble fractions (TIF)
were isolated from neurons harvested at 14 DIV as previously
described (31). PSDs from rat hippocampus were purified as
previously described (32).
Immunoprecipitation Experiments—Hippocampal neu-
rons were harvested in ice-cold solubilization buffer con-
taining 50 mMHepes, pH 7.4, 0.5 M NaCl, 0.5% Triton X-100,
0.1% deoxycholate, 1 mM EDTA, 1 mM phenylmethylsulfonyl
fluoride, 10 mM NaF, in the presence of a complete set of
proteases inhibitors (CompleteTM). Each solubilized sample
was incubated overnight with NR2B polyclonal antibody and
then for 2 h with protein A-Sepharose beads. Following this
incubation, the supernatants were removed, and the beads
were washed five times with solubilization buffer. After the
final wash, the beads were resuspended in sample buffer for
SDS-PAGE and briefly centrifuged; the supernatants were
loaded on 7% SDS-PAGE gels. Western blot analysis was
performed by computer-assisted imaging (Quantity-OneR
System; Bio-Rad).
Antibodies—Polyclonal IL-1R
antibody was purchased from Santa
Cruz Biotechnology; -CaMKII
monoclonal antibody was pur-
chased from Chemicon Interna-
tional, Inc., (Temecula, CA); mono-
clonal PSD-95 antibody was
purchased from Affinity BioRe-
agents Inc. (Golden, CO); mono-
clonal PY20 antibody and poly-
clonal pTyr-1472-NR2B antibody
were purchased from Calbiochem
(Nottingham, UK), polyclonal anti-
-tubulin was purchased from
Covance (Berkeley, CA); mono-
clonal anti-NR2A was purchased
from Zymed Laboratories Inc.;
monoclonal anti-synaptophysin
was purchased from Sigma-Aldrich;
polyclonal anti-NR2A, polyclonal
anti-NR2B, and AlexaFluor 488,
555, and 568 secondary antibodies
were purchased from Molecular
Probes (Eugene, Oregon).
Viability Assay—Neuronal cell
death was monitored over 6, 24,
48, and 72 h. In a set of experi-
ments neurons were loaded with
caffeic acid-pYEEIE or IL-1ra, and
exposed to 600 pM gp120 for 72 h.
Cell viability was measured by the
3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT)
assay (33). MTT tetrazolium salt was dissolved in serum-free
medium to a final concentration of 0.75 mg/ml and added to
the cells before the end of the experiment for 3 h at 37 °C.
The medium was then removed and the formazan was
extracted with 1N HCl:isopropyl alcohol (1:24). Absorbance
at 560 nm was read on a Multiscan reader.
Statistical Analysis—Statistical significance of differences
was determined by one-way or two-way analysis of variance
(ANOVA) followed by a multiple comparison test (Tukey’s
test). A significance level of 95% (p 0.05) was accepted.
RESULTS
gp120 Effect on Tyr-1472 Phosphorylation of NR2B Subunits:
Relevance of Glial Cells and Role of IL-1—In the last few years,
several potential Src phosphosites have been described within
the NR2B C-terminal tail (34, 35). Not only Tyr-1472 but also
Tyr-1252 and Tyr-1336 have been demonstrated as Src family
phosphorylation sites at least in transfected cells. To check for
endogenous NR2B tyrosine phosphorylation in cultured hip-
pocampal neurons co-cultured with glia, Western blotting
analysis was performed from DIV14 neuronal lysates.
No signal for both NR2B Tyr-1336 and NR2B Tyr-1252 was
found at the expected 170-kDa molecular mass (Fig. 1A). On
the other hand, a nice immunosignal for both total NR2B and
NR2B Tyr-1472 was present in the same samples. These data
FIGURE 1. Gp120 effect on Tyr-1472 phosphorylation of NR2B subunits. A, Western blotting analysis for
NR2B, NR2B-Tyr1472, NR2B-Tyr-1336 and NR2B-Tyr-1252 performed from cultured hippocampal neurons
homogenate. B, representative Western blotting and quantification of NR2B-Tyr-1472 phosphorylation after
exposure for 6 and 24 h of hippocampal neurons to gp120 in the presence of glia. At the end of treatment,
neuronswere detached fromglia and lysed forWestern blotting. Values aremean S.E. of three independent
experiments (**, p  0.01 gp120 versus C; ANOVA followed by Tukey’s test). C, Western blotting analysis for
NR2B-Tyr-1472, NR2B-Tyr-1336 and NR2B-Tyr-1252 from control and 24-h gp120-treated hippocampal neu-
rons.D, quantification of NR2B-Tyr-1472 phosphorylation after exposure of hippocampal neurons in the pres-
ence of glia IL-1ra to gp120 for 24 h. Values are mean S.E. of three independent experiments (**, p 0.01
gp120 versus C, §, p 0.05 gp120 IL-1ra versus gp120; ANOVA followed by Tukey’s test).
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suggest that Tyr-1252 and Tyr-1336 could represent Src family
phosphosites only in vitro in transfected cells, but not under our
experimental conditions in neurons.
Hippocampal neurons co-cultured with glia were treated
with 600 pM gp120 for 6 and 24 h, and NR2B subunit Tyr phos-
phorylationwas evaluated.Neuronswere then separated by glia
and lysed, and phosphorylation atNR2BTyr-1472was assessed
with a specific antibody. A significant increase of NR2B Tyr-
1472 phosphorylation was evident 24 h after gp120 treatment
(Fig. 1B, **, p  0.01 gp120 versus control), whereas 6 h of
treatment was ineffective (Fig. 1B). This effect was specifically
limited to phosphorylation processes because NR2B protein
level was not affected at the above time points (Fig. 1B). No
phosphorylation of NR2B Tyr-1336 and NR2B Tyr-1252 was
observed after 24 hof gp120 treatment (Fig. 1C), suggesting that
these two phosphosites were not involved in the effects induced
by gp120 treatment.
The effect of gp120 on NR2B Tyr-1472 phosphorylation in
neurons required the presence of glia, because it was undetect-
able when primary hippocampal neurons were exposed alone
to 600 pM gp120 for 24 h (p1472 immunostaining % of control:
controls 100 31.6, gp120: 88 33.0 n 3).
Exposure of primary glial cells to 600 pM gp120 induces a
significant release of IL-1 within 24 h (IL1, pg/ml: controls:
62.4  3.19, gp120: 139  18 (n  6); *, p  0.05 gp versus
control). The glial necessity for gp120 to trigger Tyr-1472 phos-
phorylation of the NR2B subunit together with the promotion
of IL-1 release suggest the possible involvement of this cyto-
kine in the observed effect. Hippocampal neurons co-cultured
with glia were then incubated with 600 pM gp120 in the pres-
ence or absence of 1 g/ml IL-1 receptor antagonist (IL-1ra).
IL-1ra per se did not affect basal p1472 immunostaining but
prevented gp120-induced increase of Tyr-1472 phosphoryla-
tion (Fig. 1D; **, p  0.01 versus control, §, p  0.05 versus
gp120), supporting our hypothesis.
Characterization of IL-1R, NR2B, and PSD-95 Co-
localization—The ability of IL-1ra to prevent Tyr-1472 phos-
phorylation induced by gp120, suggests the recruitment of IL-1
receptor (IL-1R) in the observed effect. We first examined the
relative abundance of IL-1R in rat hippocampal subcellular
compartments by a biochemical fractionation method, as
described previously (32). PSDwas purified from rat hippocam-
pus, and the expression of IL-1R, NR2B, as well as, pre- and
postsynaptic marker proteins in several subcellular compart-
ments was investigated by Western blot analysis. As shown in
Fig. 2A, IL-1Rwas presentwith a similar distribution in the total
homogenate (H) and in the crude membrane fraction (P2), at a
low level in the synaptosomal membrane (Syn) and in the low
speed supernatant (S1) fractions. IL-1R was enriched in the
PSD fraction and in the Triton-insoluble PSD-enriched frac-
FIGURE 2. Characterization of IL-1R, NR2B, and PSD-95 colocalization in neurons. A, isolated biochemical fractions from hippocampal tissues were
separated by SDS-PAGE, and the blots were probed with antibodies against NR2B, PSD-95, IL-1R, synaptophysin, and CaMKII. H, homogenate; S1, low speed
supernatant; P1, nuclei-associatedmembranes; S2, cytosol; P2, crudemembrane fraction; Syn, synaptosomes. B, representativeWestern blot analysis of NR2B,
PSD-95 and IL-1R from homogenate (Homo, left lane) and TIF (right lane) obtained fromDIV14 hippocampal cultures. The same amount of protein was loaded
in each lane. C,DIV14 hippocampal neurons were immunolabeled for IL-1R (left panels) or PSD-95 (middle panels). Merge data are shown on the right. Areas of
overlap in merge panels appear yellow.
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tion (TIF). In the same samples, we examined the subcellular
distribution of NR2B, CaMKII, synaptophysin (a presynaptic
marker), and PSD-95 (a postsynaptic marker). As expected,
synaptophysin was present in all subcellular compartments
analyzed, but not in the PSD or in the TIF-purified fractions,
whereas PSD-95 and CaMKII showed a similar distribution
pattern with enrichment in synaptosomes and PSD fractions
(Fig. 2A). The partition pattern of NR2B subunit closely resem-
bled IL-1R being similarly distributed in the different subcellu-
lar fractions. Amodified fractionationmethodwas then used to
analyze the presence of endogenous IL-1R at synaptic sites also
in primary hippocampal cultures; in particular, a Triton-insol-
uble postsynaptic fraction (TIF) was prepared and the presence
of IL-1R, NR2B, and PSD-95 evaluated by Western blot analy-
sis. As shown in Fig. 2B, IL-1R has a similar enrichment in the
TIF fraction compared with both NR2B and PSD-95, confirm-
ing the results obtained in rat hippocampal tissue (Fig. 2A).
We then examined by confocal labeling the distribution pat-
tern of IL-1R in cultured hippocampal neurons (Fig. 2C);
PSD-95 was used as a marker of postsynaptic structures. IL-1R
displayed a very low labeling in the somatic cytoplasm; immu-
noreactivity was present in dendrites where a punctate staining
was present. A nice colocalization pattern with PSD-95 was
observed (arrowheads, Fig. 2C), confirming the presence of
endogenous IL-1R at the postsynaptic side of cultured neurons.
Effect of gp120-induced Phosphorylation of NR2B Subunits at
Tyr-1472 on Intracellular Ca2 ([Ca2]i ) Homeostasis—Tyr
phosphorylation is a well recognized pathway adopted from
neurons to upregulateNMDA receptor function (for review see
Ref. 18) and has been involved in pathological conditions such
as ischemic neuronal death (36, 37). Neuronal injury conse-
quent to gp120 is also predominantly mediated by overactiva-
tion of NMDAR-coupled ion channels that allows excessive
Ca2 influx and a general imbalance of its homeostasis (21, 22).
We thusevaluatedwhethergp120-inducedNR2BTyrphospho-
rylation, through the release of IL-1, could be implicated in
the altered [Ca2]ihomeostasis in neurons. Primary hippocam-
pal neurons were treated with 600 pM gp120 in the presence or
absence of glia, separated at the end of treatment and moni-
tored for [Ca2]i. The exposure of primary hippocampal neu-
rons to 600 pM gp120 in the presence of glia significantly
increased neuronal [Ca2]i (Fig. 3A) after 24 h. This effect was
caused predominantly by Ca2 influx through the NR2B-
NMDA receptor channels because the addition of 10 M ifen-
prodil, a channel blocker that binds only to theNR2B subunit of
NMDA receptors, inhibited the rise of gp120-induced neuronal
[Ca2]i (Fig. 3A).
To investigate whether NR2B Tyr phosphorylation was
implicated in gp120 modulation of the NMDAR-dependent
Ca2 response, we examined the rise of gp120-induced neuro-
nal [Ca2]i in the presence of Ca-pYEEIE, a peptide inhibitor
for Src family SH2 domain (38). Thus, primary hippocampal
neurons were loaded in the absence of glia with 10 g/ml Ca-
pYEEIE, washed to remove extracellular Ca-pYEEIE, and then
exposed for 24 h in the presence of glia to 600 pM gp120. This
experimental approach allowed us to act on neurons without
interfering with the Src family signal transduction in glia. The
classical tyrosine kinases inhibitors PP1 and PP2 could not be
used for this purpose because of the reversibility of their action
upon removal (39, 40). As shown in Fig. 3B, in Ca-pYEEIE-
pretreated neurons, [Ca2]i levels were not altered by gp120
treatment. As expected, treatment with Ca-pYEEIE also pre-
vented Tyr-1472 phosphorylation (data not shown).
As previously observed for NR2B-induced phosphorylation,
gp120 ability to increase [Ca2]i requires the presence of glia,
FIGURE 3. Involvement of NR2B subunit Tyr phosphorylation, and IL-1
in gp120-induced [Ca2]i increase in primary cultures of hippocampal
neurons. A, hippocampal neurons were exposed to gp120 for 24 h in the
presence of glia with (black columns) or without (white columns) 10 M ifen-
prodil. At the end of treatment, hippocampal neurons were detached from
the glial monolayer and assayed for [Ca2]i. Values are means S.E. of nine
independent samples and represent the [Ca2]i levels in neurons at the end
of treatment (*, p 0.05 gp120 versus C, §, p 0.05 gp120 ifenprodil versus
gp120; ANOVA followed by Tukey’s test). B, hippocampal neurons were
loaded with Ca-pYEEIE, washed to remove extracellular Ca-pYEEIE and then
exposed to gp120 for 24 h in the presence of glia. Values are means S.E. of
fifteen independent samples and represent the [Ca2]i levels in neurons at
the end of treatment (*, p 0.05 gp120 versus C; ANOVA followed by Tukey’s
test).C, hippocampal neuronswere exposed for 24 h in the presence (right) or
absence (left) of glia to gp120. IL-1ra was added in part of the co-cultures
(striped column). At the end of treatment, co-cultured neurons were
detached fromglia and assessed for [Ca2]i. IL-1ra did not affect [Ca
2]i levels
per se ([Ca2]i % of control: 112  9.64). Values are means  S.E. of nine
independent samples and represent the [Ca2]i levels in neurons at the end
of treatment (*, p  0.05 gp120 versus C, §, p  0.05 gp120  IL-1ra versus
gp120; ANOVA followed by Tukey’s test).
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because 24 h of treatment with 600 pM gp120 did not affect
basal [Ca2]i in neurons exposed alone (Fig. 3C). Again, gp120-
induced [Ca2]i increase in neurons was prevented by 1 g/ml
IL-1ra (Fig. 3C), confirming the role of IL-1 and IL-1R as pos-
sible mediators of gp120 action on the NMDA receptor.
Effect of gp120 on NR2B Subcellular Localization: Role of
IL-1—It has been shown that the stability of NMDA receptors
at the synaptic membranes is regulated by both tyrosine phos-
phorylation and interaction with PSD-95 (41). In particular,
association of NMDA receptor NR2B subunits with PSD-95
and, as a direct consequence, inhibition of NR2B subunit endo-
cytosis has been suggested to bemodulated by phosphorylation
of NR2B Tyr-1472 (42–44). Based on these considerations, we
first measured by co-immunoprecipitation assay the effect of
24 h of gp120 treatment onNR2B/PSD-95 interaction. Because
of the relevant role exerted by glial cells, neurons were exposed
to gp120 in co-culture with glia under all the experimental con-
ditions (even if not stated) and separated at the end of the treat-
ment to measure the parameters of interest. As shown in Fig.
4A, gp120 induced a significant increase of PSD-95 binding to
NR2B (31.1% 6.4%, p 0.05). To confirm this result and to
examine the role of gp120 in promoting the synaptic localiza-
tion of NR2B, TIF was obtained from the control and 24-h
gp120-treated neurons and protein levels weremeasured in the
FIGURE 4. gp120 effect on NR2B subcellular localization. A, control and gp120-treated neuronal lysates were immunoprecipitated with NR2B polyclonal
antibody. Western blot analysis was performed in the immunoprecipitatedmaterial with NR2B (lower panel ) and PSD-95 (upper panel ) antibodies. Histogram
shows the quantification ofWestern blotting for PSD-95 performed in the co-immunoprecipitatedmaterial. Data are expressed as PSD-95/NR2B ratio staining
in the immunocomplex (*, p  0.05). B, Western blotting analysis performed in the homogenate (Homo) and in the TIF fraction obtained from control and
gp120-treated hippocampal cultures. The same amount of protein was loaded in each lane. gp120 treatment leads to a higher NR2B localization in the TIF
fraction (*, p 0.01) leaving unaffected CaMKII and PSD-95 immunostaining in the TIF fraction. Values are means S.E. of eight independent samples and
represent theNR2BTIF/Homo ratio stainingexpressedaspercentageof control neurons.C, hippocampal neuronswere either left untreated (control) or treated
for 24 hwith gp120 in the presence of glia IL-1ra, fixed, and immunolabeled for NR2B (left panels) or PSD-95 (middle panels). Scale bar, 10m.Merge data are
shown on the right. Areas of overlap in merge panels appear yellow. 12 neurons for each experimental condition were analyzed. D, quantification of the
confocal experiments. gp120 administration results in a redistribution of NR2B into spine-like clusters; IL-1ra treatment interferes with gp120-mediated NR2B
trafficking toward spines. The ratioof spines to cell somaordendrites fluorescencewas computedandaveraged (**,p0.01, gp120 versus control; §§,p0.01,
gp120 IL1ra versus gp120). Gp120 treatment also causes a significant increase in the percentage of NR2B clusters of the total number of PSD-95-positive
spines compared with control values (**, p 0.01, gp120 versus control; §, p 0.01, gp120 IL1ra versus gp120).
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homogenate and TIF. The same amount of proteins from
homogenate and TIF was loaded on SDS-PAGE gels for West-
ern blot analysis. As shown in Fig. 4B, gp120 treatment signifi-
cantly increased NR2B immunostaining in TIF without affect-
ing the totalNR2Bprotein level in the homogenate (**, p 0.01;
47.2  8.1%, gp120 versus control expressed as NR2B ratio
TIF/homogenate). No alteration of both PSD-95 and CaMKII
immunostaining in both homogenate and TIF was observed
following gp120 treatment.
To further confirm these data by confocal labeling, primary
hippocampal neurons were treated for 24 h with gp120, fixed
and double-labeled for NR2B and PSD-95 (Fig. 4C). In control
neurons (Fig. 4C, upper panels), NR2B signal was of a greater
intensity in the soma, but signals were clearly seen also in
PSD-95 positive “spine-like” puncta as well as, in the dendritic
shaft. In addition, NR2B immunofluorescence in “spine-like”
structures overlapped NR1 immunosignal, further confirming
the presence of the NMDA receptor
complex in the postsynaptic site
(data not shown). 24-h gp120 treat-
ment produced a more pronounced
NR2B punctuated pattern associ-
ated with a higher colocalization
degree with PSD-95 (Fig. 4C).
Quantification of NR2B relative flu-
orescence intensity in spine versus
dendritic shaft or versus soma (Fig.
4D) revealed that gp120-treated
neurons exhibited an increased flu-
orescent signal in these spine-like
structures (Fig. 4D, **, p  0.01,
gp120 versus control). In addition,
quantification of NR2B punctuated
staining revealed a significant in-
crease of NR2B immunoreactivity
in PSD-95-positive dendritic spines
compared with control values (Fig.
4D; **, p  0.01, gp120 versus Con-
trol). Both sets of data suggest a pro-
motion of NMDA NR2B subunit
redistribution to synaptic sites by
gp120.
To assess whether the effects on
NR2B localization were mediated
by IL-1, gp120 treatments were
performed in the presence of IL-1ra.
Fig. 4D shows that IL-1ra prevented
gp120-induced trafficking of the
NMDA receptor NR2B subunit (§§,
p  0.01 and §, p  0.05, gp120 
IL-1ra versus gp120); both NR2B
relative fluorescence in spines ver-
sus dendrites or soma and NR2B
immunoreactivity in PSD-95 posi-
tive dendritic spines were signifi-
cantly reduced by IL-1ra. IL-1ra per
se did not affect NR2B subcellular
distribution (Fig. 4D) or cell survival
(% of cell survival, control: 100 7.2; 24h IL-1ra: 97.4 4.45).
Previous studies have shown that membrane stabilization of
NMDAreceptors containing theNR2B subunit is regulated dif-
ferently from those containing the NR2A subunit (45). Recent
results suggest that the differential regulation of NR2A- and
NR2B-containing receptors at the synapse may depend upon
specific interactions of NR2Bwith PDZ proteins andAP-2 (44).
We thus analyzed the effects of gp120 on NR2A subunit, lack-
ing the Tyr-1472 phosphosite (Fig. 5A). No alteration of both
spine versus dendritic localization, (Fig. 5B) as well as colocal-
ization with PSD-95 was observed (Fig. 5C). In addition, no
alteration of NR2A immunostaining in TIF was observed fol-
lowing gp120 treatment (Fig. 5D) suggesting a specific effect of
the glycoprotein on NR2B subunit.
Role of Tyr-1472 Phosphorylation and Binding to PSD-95 in
NR2B Redistribution Induced by gp120—Possible molecular
mechanisms responsible for gp120-induced synaptic redistri-
FIGURE5.NR2AcolocalizationwithPSD-95aftergp120 treatment.A, hippocampalneuronswereeither left
untreated (upper panels) or treated for 24 h with gp120 (lower panels) in the presence of glia and immunola-
beled for PSD-95 (left panels) or NR2A (middle panels). Scale bar, 10 m. Merge data are shown on the right.
Areas of overlap in merge panels appear yellow. B, quantification of the confocal experiments. The ratio of
spines to dendrite fluorescence was computed and averaged. C, gp120 administration does not affect the
percentage of NR2A clusters on the total number of PSD-95-positive spines; 12 neurons for each experimental
condition were analyzed. D, Western blot analysis performed in the TIF fraction obtained from control and
gp120-treated hippocampal cultures. The same amount of protein was loaded in each lane. gp120 treatment
does not affect NR2A, PSD-95, and CaMKII localization in the TIF fraction.
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bution of NR2B subunit include Tyr-1472 phosphorylation
(see Fig. 1A) and NR2B binding with specific postsynaptic
scaffolding proteins such as PSD-95 (see Fig. 4A). These two
mechanisms can converge and lead to the same final effect;
in fact, it has been demonstrated that mutation of NR2B
Tyr-1472 disrupts the endocytic AP-2 binding site on NR2B
and that PSD-95 inhibit NR2B-mediated endocytosis (45). In
addition, recent data (44) clearly confirm that anchoring to a
PDZ protein such as PSD-95, AP-2-mediated internaliza-
tion, and phosphorylation of Tyr-1472 together play a key
role in the regulation of NR2B-containing synaptic NMDA
receptors.
Based on these observations, Ca-pYEEIE and TAT2B pep-
tides, corresponding to the last 9 amino acids C-terminal of
NR2B (fused to the TAT peptide to facilitate internalization
into living cells), were used to unravel the mechanisms modu-
latingNR2B localization in spines after 24 h of gp120 treatment.
In neurons preloaded with Ca-pYEEIE and treated with gp120,
both NR2B trafficking to spines and colocalization of NR2B
with PSD-95 were reduced (Fig. 6, A and B, **, p 0.01 versus
control; §§, p  0.01 versus gp-120). Similarly, TAT2B treat-
ment which reduces NR2B binding to PSD-95 (data not shown)
rescues NR2B neuronal distribution to control levels (Fig. 6, A
and C, **, p  0.01 versus control; §§, p  0.01 versus gp-120)
confirming the key role for PSD-95 to confine NR2B inside the
postsynaptic compartment. Furthermore, as previously
observed with Ca-pYEEIE, TAT2B also prevented gp120-in-
duced [Ca2]i increase in neurons (neuronal [Ca2]i as % of
controls: 100  8.6, n  6; gp120-treated: 152  12.7, n  7;
TAT2B gp120-treated: 106 10.8, n 6).
Effect of gp120 on PSD-95 Positive Clusters and Neuronal
Death—Reduction of spine density and neuronal survival rep-
resents two hallmarks of HAD related to cognitive decline, per-
sonality change, and motor deficits (26, 27). Under our experi-
mental conditions, no effect on PSD-95 positive clusters was
observed after 24 h of gp120 (PSD-95 clusters/50 m, controls:
27 3.2; gp120 600 pM: 25 5,n 12).On the other hand, 48 h
of gp120 treatment produced a significant reduction of total
PSD-95 clusters (Fig. 7,A andB; from24.9 4.56 to 16.5 3.28
protrusions per 50 m dendrite length; *, p 0.05 versus con-
trol) suggesting the occurrence of spine loss at this time point.
Differently, dendrites appear generally undamaged, as evi-
denced by co-staining with-tubulin used in all experiments to
check for normal dendritic branching following gp120 treat-
ment (Fig. 7A). Loss of PSD-95 clusters was counteracted in
neurons loaded with Ca-pYEEIE or with IL-1ra (Fig. 7, A/B, §,
p  0.05 versus gp120). To further strengthen this data and
quantify the effective neuronal damage, we monitored gp120-
induced cell death in hippocampal neurons.No significant neu-
ronal death was found after 6 and 24 h of gp120 treatment
(respectively, 99.6 2.49 and 91.6 5.12% of cell survival). On
the other hand, 48 and 72-h gp120 treatment resulted, respec-
tively, in about 20% (p  0.01 versus C) and 30% (**, p  0.01
versus C) of neuronal death (Fig. 7C). Both Ca-pYEEIE 10
g/ml and IL-1ra 1 g/ml prevented gp120-induced neuronal
death (72 h, Fig. 7C; §§, p 0.01 versus gp120).
DISCUSSION
The key finding of this study is that the HIV-1 glycoprotein
gp120 increases tyrosine phosphorylation of NMDA receptor
NR2B subunit through the release of IL-1 produced by the
activated glia. The activation of this pathway leads to a sus-
tained elevation of [Ca2]i in neurons and to the stabilization of
the NMDA receptor NR2B subunit at the synaptic sites, where
a significant increase of NR2B colocalization and binding to
PSD-95 was detected after 24 h of gp120 treatment. These
effects are relevant for gp120-induced neuronal death.
Our results support previous evidence suggesting that a
FIGURE 6. Effect of Ca-pYEEIE peptide and TAT-2B on gp120-induced
NR2B trafficking to spines. A, immunofluorescence of NR2B subunit of the
NMDAreceptor inhippocampal neuronsexposed togp120 in thepresenceof
glia. Hippocampal neurons were loaded with Ca-pYEEIE, washed to remove
extracellular Ca-pYEEIE and exposed for 24 h to gp120 in the presence of glia
or exposed to gp120 TAT2B. Scale bar, 10m. B and C, quantification of the
confocal experiments. The ratio of spines to dendrite fluorescence (left pan-
els) was computed and averaged (**, p  0.01, versus control; §§, p  0.01,
versus gp120). Both Ca-pYEEIE and TAT2B treatments caused a significant
reduction in the percentage of NR2B clusters of the total number of PSD-95-
positive spines (right histograms) compared with gp120 values (**, p 0.01,
versus control; §§, p 0.01, versus gp120).
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relevant pathway to neuronal injury in HAD is indirect
through release of potentially neurotoxic factors from acti-
vated glia (46–48). Thus, Tyr phosphorylation of NMDA
receptor and neuronal Ca2 increase were not evident in
neurons exposed to gp120 in absence of glia. In these exper-
imental conditions we did not detect any cell death following
gp120 exposure.4 The need of glia for gp120 to affect neu-
rons, discloses the existence of complex cell-cell interactions
possibly responsible for the delayed onset of dynamic pro-
cesses, such as phosphorylation, in neurons.
IL-1 is one of the many mediators released from glia by
gp120 involved in its pathogenic effect. Levels of IL-1 are ele-
vated in the cerebrospinal fluid of AIDS patients and at post-
mortem brain examination (8, 49), as well as in several rat brain
areas following intracerebroventricular infusion of gp120 (7,
50–54). Pharmacological manipulations, the use of antagonist
for type I IL-1 receptor (IL-1ra) and of specific antibodies to
neutralize the action of IL-1,
greatly contributed to the under-
standing of some of the effects
exerted by this cytokine in AIDS
dementia complex. In vivo, IL-1ra
and -melanocyte-stimulating hor-
mone (an endogenous hormone and
transmitter that inhibits IL-1
action, Ref. 55) blocked gp120-in-
duced memory impairment (52). In
vitro, protection from cell death was
conferred by inhibiting IL-1 action
through a specific inhibitor of inter-
leukin-1-converting enzyme, IL-1ra
(7) and an antibody against IL-1
that also prevented gp120-induced
[Ca2]i increase in neurons (9).
Although a relevant role for IL-1 in
sustaining gp120 neuronal damage
emerges, no information is available
about the molecular mechanisms
recruited by this cytokine in this
contest.
Under our experimental condi-
tions, concentrations of gp120 that
stimulate glial release of IL-1
induced Tyr-1472 phosphorylation
of NR2B and trigger a sustained ele-
vation of [Ca2]i in neurons. In
accordance with data showing that
recombinant IL-1, through IL-1R,
inducesNMDAreceptorphosphoryl-
ation by Src kinases and a consequent
facilitation of NMDA-induced
[Ca2]i increase (17), we observed
that both IL-1ra, the antagonist of
IL-1R type I, and Ca-pYEEIE, an
inhibitor for Src family SH2 domains
(35), prevent gp120 effects.
As previously mentioned, besides cytokines, gp-120 acti-
vated glia release othermediators, whichmay impair the re-up-
take of glutamate by astrocytes and induce astrocytic glutamate
release (56–58). Furthermore, glutamate is also spontaneously
released by primary hippocampal neurons in culture. Thus,
gp120-released IL-1 may prime the NMDA receptors pro-
moting the phosphorylation at Tyr-1472 and contributing to
the potentiation of the glutamate signal through NMDAR.
Overactivation of NMDA receptor-coupled ion channels and
the resulting influx of Ca2 appear to be central to HIV-related
neuronal damage (22).
Electrophysiological recordings from neurons show that
NMDA currents are governed by a balance between tyrosine
phosphorylation and dephosphorylation (59). Whether phos-
phorylation causes the increase in NMDA receptor gating still
remains unclear (18). On the other hand, tyrosine phosphoryl-
ation of NR2 subunits might also prevent the removal of signal-
ing molecules from the NMDAR complex by protecting the
subunits against degradation from the calcium-activated pro-4 B. Viviani, unpublished observation.
FIGURE 7. Loss of PSD-95 positive clusters and neuronal death after gp120 treatment: modulation by
Ca-pYEEIE and IL-1ra. A, hippocampal neurons were either left untreated (control) or treated for 48h with
gp120 in the presence of glia, fixed, and immunolabeled for -tubulin (left panels) or PSD-95 (middle panels).
Merge data are shown on the right. Areas of overlap in merge panels appear yellow. B, number of PSD-95-
positive clusters per 50mof dendrite length in neurons, loaded (gray columns) or not with Ca-pYEEIE or with
IL-1ra, after 48 h of treatment with gp120 in the presence of glia (*, p 0.05 versus control; §, p 0.05 versus
gp120). C, hippocampal neurons were loaded with Ca-pYEEIE or with IL-1ra and then exposed to gp120 in the
presence of glia for 72 h. MTT test was performed to assay cell viability. gp120-induced cell death was pre-
vented by both Ca-pYEEIE and IL-1ra. Values aremeans S.E. of two independent experiments in triplicate, **,
p 0.01 versus control; §§, p 0.01 versus gp120).
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tease, calpain (41). Furthermore, studies on recombinant
NMDA receptors indicate that their association with the clath-
rin-mediated endocytosis machinery, a complex of proteins
involved in the removal of receptors from the cell surface, is
regulated by Src-mediated tyrosine phosphorylation of
NMDAR subunits (60, 61). The NR2B Tyr-1472 consensus
domain is part of the internalization signal motif, a binding
domain for the adaptor protein complex AP2, which associates
with endocytic clathrin-coated vesicles. In addition, Src family
tyrosine kinases have been shown to interact with NMDA
receptors by binding to the scaffolding protein PSD-95 (62).
This interaction is strictly correlated to tyrosine phosphoryla-
tion of the NMDA receptors subunits (41, 43, 63). Finally,
recent results show that stabilization of NR2B-containing
receptors at the synapse is dynamically regulated by binding to
a PDZ protein such as PSD-95 and internalization through an
interaction with AP-2 (44). With this view, NR2B-PDZ protein
interaction may keep Tyr-1472 phosphorylated, and conse-
quently unable to interact with AP-2 (44). The final result of
this event is an increased localization of NR2B within the
postsynaptic compartment, probably through prevention of
endocytosis of NR2B-containing synaptic receptors (43). Our
results suggest that all these mechanisms may be recruited by
gp120, through IL-1 release. We observed a sustained eleva-
tion of Ca2 in neurons exposed to gp120. Such an increase
occurs through the NR2B subunit: ifenprodil, a blocker that
selectively binds to this subunit, inhibited this effect. In addi-
tion, gp120 increases both the binding of NR2B subunit with
PSD-95 and its enrichment in spine.
Tyrosine phosphorylation and PSD-95 binding appear to be
important in the occurrence of gp120-induced NR2B localiza-
tion andCa2 homeostasis unbalance because bothCa-pYEEIE
and TAT2B, peptides analogous to the C-terminal domains of
NR2B, prevent these effects. Therefore, gp120 by phospho-
rylating the NR2B tyrosine 1472 could prevent the assembly of
the clathrin-mediated endocytosis machinery at the NMDA
receptors and thereby prevent the internalization of NMDA
receptors. Alternatively, tyrosine phosphorylation of NR2 sub-
units could be involved in the trafficking ofNMDA receptors to
the cell surface (42). Again, IL-1ra inhibits Tyr-1472 phospho-
rylation, NR2B enrichment of spine like structures and neuro-
nal cell death supporting the role of this cytokine asmediator of
gp120 action and its involvement in the cascade of events
induced by Tyr phosphorylation.
Altered tyrosine phosphorylation of NMDA receptor NR2
subunits has been observed in pathological conditions such as
transient ischemia (36, 37, 64), epilepsy (65), and in amyloid-
peptide-treated neurons (66) suggesting its involvement in
neuronal damage progression.
Our data together with the observation that tyrosine phos-
phorylation of theNMDAreceptor have been also implicated in
exacerbation of neuronal cell loss induced by the pathogenic
HIV-1 protein TAT (67), suggest a possible involvement of this
pathway inHADaswell. Accordingly, we show that Ca-pYEEIE
prevents neuronal death. It would have been interesting to eval-
uate whether stabilization at the membrane of NR2B-contain-
ing receptor selectively induced neuronal demise. In fact,
NR2A- and NR2B-containing receptors have distinct biophys-
ical properties, including sensitivity to glutamate and deactiva-
tion time (68, 69), and interact differently with postsynaptic
signal transduction complexes (70). As a result, different recep-
tor subtypes may serve distinct physiological or pathological
functions in neurons. Unfortunately, because of their toxicity,
which was evident at 48 h (data not shown), we could not eval-
uate whether ifenprodil and TAT-2Bmodulated spines simpli-
fication and neuronal death. Nevertheless, the observation that
gp120 enhances the presence of the NR2B subunit at the
postsynapticmembrane, but not of theNR2A subunit, supports
this possibility under our experimental conditions.
In conclusion, our results provide a molecular basis to link
endogenous IL-1 produced in a pathological condition and
deregulation of Ca2 neuronal homeostasis because of an over-
activation of theNMDA response. Overall, the chance to atten-
uate neuronal damage blocking NMDARs has been attempted
over the years but with scarce results, perhaps because of the
fundamental implication of these receptors in the physiology of
neurons. Thus, determining how IL-1, released in a patholog-
ical situation, affects neurons would provide new insight to the
general comprehension of acute and chronic pathological con-
ditions associated with specific inflammatory mediators and
would offer significant promise in the identification of possible
targets for a selective pharmacological intervention on
NMDARs.
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